| 185.95 2.61 (1.42%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 224.58 | 1-year : | 262.31 |
| Resists | First : | 192.27 | Second : | 224.58 |
| Pivot price | 178.72 |
|||
| Supports | First : | 177.67 | Second : | 168.63 |
| MAs | MA(5) : | 180.63 |
MA(20) : | 180.82 |
| MA(100) : | 181.62 |
MA(250) : | 155.05 |
|
| MACD | MACD : | -1.1 |
Signal : | -2 |
| %K %D | K(14,3) : | 66 |
D(3) : | 50.7 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 202.41 | Low : | 115.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BIIB ] has closed below upper band by 3.7%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 187.97 - 188.69 | 188.69 - 189.41 |
| Low: | 180.35 - 181.22 | 181.22 - 182.09 |
| Close: | 184.55 - 185.88 | 185.88 - 187.21 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Tue, 21 Apr 2026
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up - TradingView
Mon, 20 Apr 2026
Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance
Mon, 20 Apr 2026
Biogen Inc (BIIB) Shares Surge 3.4% -- What GF Score of 72 Tells Investors - GuruFocus
Mon, 20 Apr 2026
Biogen to buy China rights to immune disease drug for up to $850M - Seeking Alpha
Mon, 20 Apr 2026
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region - Biogen
Mon, 20 Apr 2026
Biogen pays $100M to take full global control of felzartamab - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 147 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 98.5 (%) |
| Shares Short | 3,830 (K) |
| Shares Short P.Month | 4,200 (K) |
| EPS | 8.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 124.36 |
| Profit Margin | 13 % |
| Operating Margin | 19.6 % |
| Return on Assets (ttm) | 6.1 % |
| Return on Equity (ttm) | 7.3 % |
| Qtrly Rev. Growth | -7.1 % |
| Gross Profit (p.s.) | 53.21 |
| Sales Per Share | 67.38 |
| EBITDA (p.s.) | 24.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2,200 (M) |
| Levered Free Cash Flow | 1,980 (M) |
| PE Ratio | 21.13 |
| PEG Ratio | 3.6 |
| Price to Book value | 1.49 |
| Price to Sales | 2.75 |
| Price to Cash Flow | 12.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|